Understanding Your Biopsy Report
At a Glance
A scalp biopsy for Graham Little-Piccardi-Lassueur Syndrome (GLPLS) looks for active inflammation, scarring (fibrosis), and specific proteins to confirm the disease and rule out look-alikes like lupus. Understanding these pathology terms helps you and your doctor plan the right treatment.
A pathology report is the “map” of your condition, providing the evidence your doctor needs to confirm a diagnosis of Graham Little-Piccardi-Lassueur Syndrome (GLPLS). Because GLPLS is a clinical variant of Lichen Planopilaris (LPP), the technical terms on your report will often describe the classic patterns of LPP [1][2]. Understanding these terms can help you participate in your care and ensure no detail is overlooked.
Decoding the Technical Language
When a pathologist looks at your scalp tissue under a microscope, they are looking for specific markers of an autoimmune attack. Here are the most common terms you might see:
- Lymphocytic Infiltrate: This refers to a group of white blood cells (lymphocytes) gathered around the hair follicle. In GLPLS, they specifically cluster near the top and middle sections of the follicle (the infundibulum and isthmus), signaling an active immune attack [3][4].
- Interface Dermatitis: This describes inflammation occurring exactly where the hair follicle cells meet the surrounding skin tissue. This is the “front line” where damage to the follicle occurs [5].
- Perifollicular Fibrosis: This is the technical term for scarring. It means the body is replacing the hair follicle with tough, fibrous connective tissue. If the report says “concentric fibrosis,” it means the scar tissue is wrapping around the follicle like a ring [6][7].
- Civatte Bodies (Colloid Bodies): These are tiny, rounded structures that represent skin cells that have died due to the inflammatory attack [1].
- Loss of Follicular Ostia: This means the “pores” or openings where hair emerges are no longer visible. This is a primary sign of cicatricial (scarring) alopecia [8].
The “Completeness Checklist”
To be certain of a GLPLS diagnosis and to rule out “look-alikes” like Lupus, your report should ideally address the following data points:
- [ ] CD123 Immunohistochemistry: This stain is used to count “plasmacytoid dendritic cells.” If there are large clusters (10 or more), the diagnosis is more likely to be Discoid Lupus Erythematosus (DLE) rather than GLPLS [9].
- [ ] Elastic Stain (e.g., Verhoeff-Van Gieson): This helps the pathologist see if the elastic fibers in your skin have been destroyed, which happens in specific patterns in LPP and GLPLS [10].
- [ ] Direct Immunofluorescence (DIF): This test looks for immune proteins. In GLPLS/LPP, it often shows “shaggy” deposits of a protein called fibrinogen. If it shows granular deposits of IgG or IgM, it points toward Lupus [11].
What “Fibrosis” Means for You
If your report highlights significant fibrosis, it indicates that the immune system has already completed its attack in that specific area, replacing the follicle with a scar [12]. While this means hair cannot regrown in those specific scarred spots, it does not mean the rest of your hair is lost. Identifying fibrosis helps your doctor determine if they need to use aggressive treatments to “put out the fire” of active inflammation elsewhere or if the disease has become “burnt out” [7]. The goal of treatment is always to prevent new areas of fibrosis from appearing [7][6].
Common questions in this guide
What does perifollicular fibrosis mean on my scalp biopsy?
How does a biopsy tell the difference between GLPLS and lupus?
What is a lymphocytic infiltrate on a hair loss pathology report?
Can my hair regrow if the biopsy shows fibrosis?
Questions to Ask Your Doctor
Curated prompts to bring to your next appointment.
- 1.Does my report mention 'clusters of 10 or more CD123+ cells,' and how does that affect the diagnosis of GLPLS versus Lupus?
- 2.Based on the level of 'fibrosis' seen in this biopsy, what percentage of my follicles in this area are permanently lost?
- 3.Was 'Direct Immunofluorescence' (DIF) performed to look for fibrinogen or antibody deposits?
- 4.Is the 'lymphocytic infiltrate' described as mild, moderate, or severe, and what does that tell us about how active the disease is right now?
Questions For You
Tap a prompt to share your answer — we'll use it plus this page's context to start a tailored conversation.
References
References (12)
- 1
[Not Available].
Kakizaki P, Donati A, Valente NY, Romiti R
Dermatology online journal 2015; (21(7)).
PMID: 26436976 - 2
Graham-Little-Piccardi-Lassueur syndrome.
Divine J, Rudnick EW, Lien M
Cutis 2019; (103(5)):E8-E11.
PMID: 31233585 - 3
Exploring the association between lichen planopilaris, cardiovascular and metabolic disorders.
Conic RRZ, Maghfour J, Damiani G, Bergfeld W
Journal of the European Academy of Dermatology and Venereology : JEADV 2021; (35(11)):e826-e828 doi:10.1111/jdv.17513.
PMID: 34242427 - 4
Lichen planopilaris in a Latin American (Chilean) population: demographics, clinical profile and treatment experience.
Mardones F, Shapiro J
Clinical and experimental dermatology 2017; (42(7)):755-759 doi:10.1111/ced.13203.
PMID: 28748570 - 5
Epithelial-to-Mesenchymal Stem Cell Transition in a Human Organ: Lessons from Lichen Planopilaris.
Imanishi H, Ansell DM, Chéret J, et al.
The Journal of investigative dermatology 2018; (138(3)):511-519 doi:10.1016/j.jid.2017.09.047.
PMID: 29106928 - 6
Naked Hair Shafts as a Marker of Cicatricial Alopecia.
Doytcheva K, Tan T, Guitart J, et al.
The American Journal of dermatopathology 2018; (40(7)):498-501 doi:10.1097/DAD.0000000000001075.
PMID: 29293128 - 7
Central Centrifugal Cicatricial Alopecia: New Insights and a Call for Action.
Dlova NC, Salkey KS, Callender VD, McMichael AJ
The journal of investigative dermatology. Symposium proceedings 2017; (18(2)):S54-S56 doi:10.1016/j.jisp.2017.01.004.
PMID: 28941495 - 8
Trichoscopic Differentiation in Alopecia: Retrospective Case Series Comparing Lichen Planopilaris, Discoid Lupus Erythematosus, and Alopecia Areata.
Kaya G
JMIR dermatology 2025; (8()):e83463 doi:10.2196/83463.
PMID: 41264867 - 9
Different distribution patterns of plasmacytoid dendritic cells in discoid lupus erythematosus and lichen planopilaris demonstrated by CD123 immunostaining.
Rakhshan A, Toossi P, Amani M, et al.
Anais brasileiros de dermatologia 2020; (95(3)):307-313 doi:10.1016/j.abd.2019.11.005.
PMID: 32299739 - 10
Value of CD123 Immunohistochemistry and Elastic Staining in Differentiating Discoid Lupus Erythematosus from Lichen Planopilaris.
Aslani FS, Sepaskhah M, Bagheri Z, Akbarzadeh-Jahromi M
International journal of trichology 2020; (12(2)):62-67 doi:10.4103/ijt.ijt_32_20.
PMID: 32684677 - 11
Direct immunofluorescence findings in cicatricial alopecia: A retrospective study of 155 cases.
Agarwal R, Singh M, Dahiya R, et al.
Indian journal of pathology & microbiology 2019; (62(1)):103-106 doi:10.4103/IJPM.IJPM_428_18.
PMID: 30706869 - 12
Exploring Remission Dynamics and Prognostic Factors in Lichen Planopilaris: A Retrospective Cohort Study.
Lyakhovitsky A, Zilbermintz T, Segal Z, et al.
Dermatology (Basel, Switzerland) 2024; (240(4)):531-542 doi:10.1159/000538355.
PMID: 38574470
This page explains GLPLS biopsy and pathology terminology for educational purposes. Always consult your dermatologist or pathologist to interpret your specific biopsy results and formulate a treatment plan.
Get notified when new evidence is published on Graham Little-Piccardi-Lassueur syndrome.
We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.